Form 4: vTv Therapeutics Inc. Executive Acquires 45,000 Stock Options
SEC Form 4 Filing
Michael Stephen Tung, EVP & CFO of vTv Therapeutics Inc., acquired 45,000 employee stock options on May 19, 2025, at an exercise price of $21.25.
Summary
- On May 19, 2025, Michael Stephen Tung, the EVP & CFO of vTv Therapeutics Inc., was granted 45,000 employee stock options.
- The exercise price for these options is $21.25 per share.
- The options vest 25% on the first anniversary of the grant date and the remaining portion vests quarterly over three years, contingent upon continued employment.
- The options expire on May 19, 2035.
Sentiment
Score: 6
Explanation: The document is a standard SEC Form 4 filing, indicating a routine grant of stock options. The sentiment is neutral as it simply reports a transaction.
Positives
- The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing him to improve the company's performance.
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to attract and retain talent and align management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
- The vesting schedule of 25% on the first anniversary and the remainder quarterly over three years is a typical vesting arrangement.
- Comparing the exercise price and the number of options granted to similar companies and executive roles would provide a more comprehensive assessment of the grant's value.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the executive to increase shareholder value.
- Employees may see the grant as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 05/19/2025 | Date of the transaction: Michael Stephen Tung acquired 45,000 employee stock options. |
| 05/19/2025 | First vesting date: 25% of the options vest on the first anniversary of the grant date. |
| 05/21/2025 | Date of signature of the report. |
| 05/19/2035 | Expiration date of the options. |
Keywords
stock options, Form 4, executive compensation, vTv Therapeutics, VTVT, Michael Stephen Tung, EVP & CFO, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.